Who is sponsoring NCT03780517?

NCT03780517 is sponsored by Boston Pharmaceuticals.

What drugs are being tested in NCT03780517?

Interventions in NCT03780517: BOS172738.

What condition does NCT03780517 study?

NCT03780517 studies Advanced Nonhaematologic Malignancies.

Is NCT03780517 still recruiting?

NCT03780517 is currently completed. Last updated 30 October 2023.

Last reviewed 2023-10-30 · How we verify

NCT03780517

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors

Completed Phase 1 Last updated 30 October 2023

What this trial tests

Phase 1 trial testing BOS172738 in Advanced Nonhaematologic Malignancies in 117 participants. Completed in 26 September 2023.

Timeline

12 December 2018

Primary endpoint
26 September 2023

26 September 2023

Quick facts

Lead sponsor	Boston Pharmaceuticals
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	117
Start date	12 December 2018
Primary completion	26 September 2023
Estimated completion	26 September 2023
Sites	21 locations across France, Hong Kong, Belgium, Taiwan, South Korea, United States, Spain

Drugs / interventions tested

BOS172738 — full drug profile →

Conditions studied

Advanced Nonhaematologic Malignancies — all drugs for Advanced Nonhaematologic Malignancies →

Sponsor

Boston Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Advanced Nonhaematologic Malignancies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will be conducted to assess the safety and tolerability of BOS172738 when administered to patients with advanced solid tumors with rearranged during transfection (RET) gene alterations and also to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of BOS172738.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019.
Maniakas A, Dadu R, Busaidy NL, Wang JR, et al · · 2020 · cited 266× · PMID 32761153 · DOI 10.1001/jamaoncol.2020.3362
Targeted therapy in advanced non-small cell lung cancer: current advances and future trends.
Majeed U, Manochakian R, Zhao Y, Lou Y. · · 2021 · cited 193× · PMID 34238332 · DOI 10.1186/s13045-021-01121-2
Precision therapy for RET-altered cancers with RET inhibitors.
Thein KZ, Velcheti V, Mooers BHM, Wu J, et al · · 2021 · cited 123× · PMID 34391699 · DOI 10.1016/j.trecan.2021.07.003
Advances in Targeting RET-Dependent Cancers.
Subbiah V, Cote GJ. · · 2020 · cited 119× · PMID 32094155 · DOI 10.1158/2159-8290.cd-19-1116
Updates on the Management of Thyroid Cancer.
Araque KA, Gubbi S, Klubo-Gwiezdzinska J. · · 2020 · cited 115× · PMID 32040962 · DOI 10.1055/a-1089-7870
Tyrosine Kinase Receptors in Oncology.
Esteban-Villarrubia J, Soto-Castillo JJ, Pozas J, San Román-Gil M, et al · · 2020 · cited 72× · PMID 33198314 · DOI 10.3390/ijms21228529
Therapeutic strategies in RET gene rearranged non-small cell lung cancer.
Drusbosky LM, Rodriguez E, Dawar R, Ikpeazu CV. · · 2021 · cited 55× · PMID 33771190 · DOI 10.1186/s13045-021-01063-9
RET kinase inhibitors for <i>RET</i>-altered thyroid cancers.
Vodopivec DM, Hu MI. · · 2022 · cited 44× · PMID 35756966 · DOI 10.1177/17588359221101691

Verify or expand the search:

Other Boston Pharmaceuticals trials

Trials by the same sponsor.

NCT04880031 — A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an · Phase 2 · completed
NCT04221906 — Study to Evaluate the Safety and Antipsoriatic Efficacy of BOS-475 in a Psoriasis Plaque Test · Phase 1 · completed
NCT04163263 — Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Repeat Topical Application o · Phase 1 · completed
NCT04514237 — Study to Determine the Relative Bioavailability, Single and Repeat Dose Pharmacokinetics, Safety and Tolerability of BOS · Phase 1 · completed
NCT03977155 — Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predomina · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03780517 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Boston Pharmaceuticals
Last refreshed: 30 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03780517.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing